Biotech Values

[DewDiligence]

Covered VRTX short @33.69 for a 15% profit in five days. VRTX has now retraced nearly all of the rise from the January 9 PR about VX-950, so the backlash against the hype surrounding this product has just about played itself out, IMHO.

For the first time in a while, I am short no biotech stocks (but am still short SBUX).

In the past few months I've shorted and covered six drug/biotech stocks at a profit: ALKS OSIP TELK ASPM AGN and VRTX.